Plain-English translation of NCT06673381 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study—meaning researchers will watch and measure, not give new treatment—that looks at a specific blood test in heart attack patients. The test measures the ratio between inflammation marker (high sensitivity C-reactive protein) and albumin, a protein in your blood. Researchers want to see if this ratio can predict which patients will have serious heart problems while in the hospital.
Heart attack patients face different levels of risk for dangerous complications like heart failure or dangerous heartbeat rhythms while hospitalized. This study is trying to find a simple blood test that doctors can use right away to identify which patients need closer monitoring or more aggressive care.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you would have a blood sample taken when you arrive at the hospital—this is a routine part of heart attack care. Researchers will measure two specific proteins in your blood and calculate a ratio. You'll be divided into two groups based on your ratio (high or low), and doctors will monitor you during your hospital stay to see if you develop any serious heart complications. The study ends when you leave the hospital.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Egypt
Enrollment target
~240 participants
Started
November 2024
Primary completion
November 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Amira Elbasuony, resident
Sohag University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.